On Nov. 29, 2020, Moderna announced a supply agreement with the United Kingdom (UK) government for an additional 2 million doses of mRNA-1273, Moderna’s vaccine candidate against COVID-19, to the UK beginning in March 2021. To-date, the UK government had secured 7 million doses of mRNA-1273.

Moderna announced that the independent, U.S. NIH-appointed Data Safety Monitoring Board (DSMB) for the Phase 3 study of mRNA-1273, had informed Moderna that the trial has met the statistical criteria pre-specified in the study protocol for efficacy, with a vaccine efficacy of 94.5%. This study, known as the COVE study, enrolled more than 30,000 participants in the U.S. and was being conducted in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID)